Navigation Links
Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
Date:9/2/2008

ong patients in the treatment group receiving the combination of bortezomib and mapatumumab at 20 mg/kg, vs. no complete responses in the group receiving bortezomib alone.

-- Clinical responses were observed in 51.4% (18/35) of patients in the treatment group receiving bortezomib alone (0 complete and 18 partial). The response rate observed for bortezomib in the current study compares with a response rate identified in the FDA-approved bortezomib label of approximately 38%.

-- Clinical responses were observed in 50.0% (18/36) of patients in the treatment group receiving the combination of bortezomib and mapatumumab at 20 mg/kg (3 complete and 15 partial).

-- Clinical responses were observed in 30.3% (10/33) of patients in the treatment group receiving the combination of bortezomib and mapatumumab at 10 mg/kg (0 complete and 10 partial).

-- Stable disease was observed in approximately a third of the patients on study and was comparable across all treatment groups.

The multiple myeloma study is ongoing, and 58 patients in this study have not yet experienced disease progression and continue to be treated and/or followed.

About the HGS-ETR1 Proof-of-Concept Trials

The HGS-ETR1 proof-of-concept phase currently includes three randomized trials to evaluate its potential in combination with chemotherapy for the treatment of specific cancers:

-- Patients in the multiple myeloma trial will continue on treatment until the progression of disease, and HGS expects to have final data available from this study in 2009, including data on the important secondary endpoint of progression-free survival.

-- In August 2008, the Company completed the enrollment and initial dosing of patients in a randomized Phase 2 trial of HGS-ETR1 (10 mg/kg or 30 mg/kg) in combination with paclitaxel and carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC); initial data from the study are anticipated
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Aug. 29, 2014 Does your doctor know what ... doctors have recommended marijuana to the over 112,000 currently registered ... the majority of the other roughly 20,300+ active physicians listed ... little about it – even though a poll in February ... say they have tried it. "With marijuana ...
(Date:8/29/2014)... 2014 According to the ... Services (Equipment, Reagent, Primer, Probe, Custom Oligos), End-User ... Gene Synthesis, NGS, DNA, RNAi) - Global Forecast ... Synthesis Market is expected to reach $1,712.1 Million ... at a CAGR of 9.8% from 2014 to ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
Breaking Medicine Technology:Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 2Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 3Oligonucleotide Synthesis Market Worth $1,712.1 Million by 2019 4Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3
... to whole range ... of Phase II, III and IV Clinical Trials, ... in off-the-shelf and custom supply chain software for the,biopharmaceutical, ... its tcVisualize(TM) 3.0 clinical trial supply simulator. The,latest generation ...
... the,European Society of Cardiology Congress 2007 (ESC Congress 2007) ... clinical benefits compared to a bare metal stent in ... no differences in safety. At five-year follow-up, the ... to be significantly less likely than the patients in ...
Cached Medicine Technology:Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 2Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 3Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 4Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety 5
(Date:8/30/2014)... Daily Gossip reveals in its review a program ... program, who shows a unique formula to get inside a ... says that the program goes beyond mere attraction and actually ... review indicates that the program was created by dating expert ... techniques to make a man feel emotionally addicted. , Learn ...
(Date:8/30/2014)... (PRWEB) August 30, 2014 The Plastic ... in New Jersey and even in the U.S. to ... takes inches off of patients’ waists with deep-tissue heating. ... in small sections, Vanquish is more inclusive to target ... Patients lay comfortably under panels about one inch away ...
(Date:8/30/2014)... 30, 2014 Ticket Down ... Tennis Championship tickets in NYC. This popular ... US-OPEN-2014 for all day session, evening session, courtside seats, ... for this prestigious Grand Slam Tournament. , The 2014 ... , US Open Tennis Championship: Men's/Women's 3rd Round - ...
(Date:8/30/2014)... a common problem millions of American cope with every day. While ... for some, it can have a crippling impact on social activity ... mood swings and depression. , Those struggling with acne are ... some cases, that can make the problem even worse. Instead of ... quest for clearer skin can now view acne treatment reviews ...
(Date:8/30/2014)... New York (PRWEB) August 30, 2014 ... incretin mimetic claims continue to move forward in U.S. ... issued by AstraZeneca PLC on July 31, 2014, Byetta ... named in 409 product liability claims that allege the ... documents indicate that many of these claims are pending ...
Breaking Medicine News(10 mins):Health News:Make Him Desire You Review Reveals Powerful Formula to Make a Man Emotionally Addicted 2Health News:NJ Top Docs Presents, The Plastic Surgery Group 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 2Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 3Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 4Health News:US Open Tennis Tickets: Ticket Down Slashes Ticket Prices for Labor Day Weekend Sessions and More 5Health News:Acne Treatment Reviews Added to Popular Treatment Website 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 2Health News:Byetta Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Settlements in More than 80 Cases 3
... of a dedicated pediatric imaging department (with dedicated pediatric computed ... radiation dose delivered to the patient, according to a study ... American College of Radiology. ... outweigh the potential long-term risk of radiation. To minimize the ...
... mammography screening every other year outweigh the potential harms for ... risk of developing breast cancer -- a finding that could ... researchers also found greater harms from screening done with digital ... three national research groups, are published in the May 1 ...
... , MONDAY, April 30 (HealthDay News) -- ... to remove the esophagus of patients with esophageal cancer ... compared to traditional open surgery, a new study finds. ... this less-invasive procedure have much shorter hospital stays and ...
... way deaf and hard-of-hearing students learn are multifaceted: ... skills in both American Sign Language and spoken ... learning strategies. Further understanding of these unique ... particularly in science, technology, engineering and mathematics, the ...
... born every hour addicted to opiate drugs in the United ... In the research published April 30 in the ... that diagnosis of neonatal abstinence syndrome, a drug withdrawal syndrome ... 2009, the estimated number of newborns with the syndrome was ...
... , MONDAY, April 30 (HealthDay News) -- Just ... healthy, a veterinarian says. "Dogs should get exercise at ... each session for small dogs and 30 to 40 minutes ... at the Veterinary Medical Teaching Hospital at Kansas State University ...
Cached Medicine News:Health News:Use of dedicated pediatric imaging departments for pediatric CT reduces radiation dose 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 2Health News:Research examines when benefits of screening mammography outweigh the harms for women in their 40s 3Health News:Less-Invasive Surgery for Esophageal Cancer Might Be Safer 2Health News:Grant awarded to help improve problem-solving skills for deaf and hard-of-hearing students 2Health News:About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows 2Health News:About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows 3Health News:Exercise Twice a Day Vital for Your Dog's Health, Expert Says 2
MultiWash Advantage is a versatile microplate washer engineered for reliability. It is designed for lab environments to help streamline their daily processes....
Synchron Hemoglobin A1c (HbA1c) utilizes two unique cartridges, Hb and A1c, to determine HbA1c concentration as a percentage of total hemoglobin....
... Monoclonal antibody method for HbA1c provides outstanding ... 99% agreement with the HPLC method(1) , ... a CV of 2.6%* means your results ... (NGSP) certified method, as recommended by the ...
The sole coagulation analyzer in the world that uses a unique dry reagent card....
Medicine Products: